Get the Stockscreener App
7.405
0.20%
-0.015
After Hours:
7.48
0.075
+1.01%
Trevi Therapeutics Inc stock is traded at $7.405, with a volume of 1.13M.
It is down -0.20% in the last 24 hours and up +35.37% over the past month.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
See More
Previous Close:
$7.42
Open:
$7.35
24h Volume:
1.13M
Relative Volume:
0.62
Market Cap:
$868.55M
Revenue:
-
Net Income/Loss:
$-29.07M
P/E Ratio:
-25.53
EPS:
-0.29
Net Cash Flow:
$-31.85M
1W Performance:
-5.55%
1M Performance:
+35.37%
6M Performance:
+87.94%
1Y Performance:
+132.86%
1-Day Range:
$7.32
$7.6091
1-Week Range:
$7.305
$7.97
52-Week Range:
$2.36
$8.11
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Name
Trevi Therapeutics Inc
Sector
Industry
Phone
203-304-2499
Address
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
7.405 | 903.42M | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Reiterated | Needham | Buy |
| Mar-10-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-12-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-30-24 | Initiated | Raymond James | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-12-23 | Initiated | B. Riley Securities | Buy |
| Nov-22-22 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-19 | Initiated | Needham | Buy |
| Jun-03-19 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | Stifel | Buy |
View All
Trevi Therapeutics Inc Stock (TRVI) Latest News
Trevi Therapeutics Q2 Earnings: Key Updates on Chronic Cough Drug Trials Coming August 7 - Stock Titan
Is it the right time to buy Trevi Therapeutics Inc. stockEntry Signal Growth Plan For Every Investor - jammulinksnews.com
Trend analysis for Trevi Therapeutics Inc. this weekLow Risk Buy Zone Opportunity Watch Ongoing - metal.it
Why Trevi Therapeutics Inc. stock attracts strong analyst attentionScalable Strategy with Chart Confirmation - Newser
Has Trevi Therapeutics Inc. formed a bullish divergenceFundamental + Technical Combined Watchlist - Newser
Predicting Trevi Therapeutics Inc. trend using moving averagesRisk Balanced Picks for Safer Trading - Newser
Bullish Candlestick Pattern Forms in Trevi Therapeutics Inc.Weekly Stock Opportunity Radar Scanner Activated - metal.it
Developing predictive dashboards with Trevi Therapeutics Inc. dataDaily Market Entry Strategy with Tools - Newser
Trevi Therapeutics Inc. Earnings Report Breakdown: What Investors Should KnowWeekly Hot Stocks Based on Volume Flow - Newser
Trevi Therapeutics Inc.’s Beta Climbs After Market VolatilityAI Screening for Swing Trade Picks Finds Momentum - metal.it
Why did Trevi Therapeutics' operating expenses surge in Q3 2024? - AInvest
Trevi Therapeutics Leadership Showcases Chronic Cough Treatment Progress at Major August Biotech Conferences - Stock Titan
Trevi Therapeutics Inc. Shows Early Signs of Technical StrengthFast Exit and Entry Strategy Guide Offered - metal.it
Trevi Therapeutics Inc. Stock Support and Resistance Levels You Should Know Stable Profit Zone and Loss Control Analysis - beatles.ru
Why is Trevi Therapeutics Inc. stock attracting strong analyst attentionBreakthrough capital growth - jammulinksnews.com
How strong is Trevi Therapeutics Inc. company’s balance sheetAchieve fast wealth growth with smart picks - jammulinksnews.com
Is Trevi Therapeutics Inc. a growth stock or a value stockBuild a diversified portfolio for steady growth - jammulinksnews.com
Trevi Therapeutics Inc. Stock Analysis and ForecastUnbelievable profit margins - PrintWeekIndia
What analysts say about Trevi Therapeutics Inc. stockConsistent wealth multiplication - PrintWeekIndia
Should I buy Trevi Therapeutics Inc. stock before earningsFree Capital Allocation Plans - jammulinksnews.com
What drives Trevi Therapeutics Inc. stock priceUnprecedented profit potential - PrintWeekIndia
Is Trevi Therapeutics Inc. a good long term investmentHigh-profit trading signals - Autocar Professional
Will Trevi Therapeutics Inc. stock split in the near futureMarket-leading growth rates - jammulinksnews.com
How Trevi Therapeutics Inc. stock reacts to Fed policy changesFree Risk Assessment Services - jammulinksnews.com
The Business Case For Buying Trevi Therapeutics Inc (NASDAQ: TRVI) Stock Now - Stocksregister
Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference - Seeking Alpha
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism - Eastern Progress
How Trevi Therapeutics Inc. stock performs during market volatilityFree Access to Investors Club - Newser
Trevi Therapeutics Inc Stock (TRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):